Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Letter of Offer to the Public Shareholders of Aspira Pathlab & Diagnostics Ltd ("Target Company").
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 10.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aftertrade Broking Pvt Ltd, acting as Manager to the Offer, has submitted the Letter of Offer on behalf of 5 Acquirers (Mr. Arvind Karsandas Bhanushali, Mrs. Deepali Arvind Bhanushali, Mr. Jay Arvind Bhanushali, Mr. Nikunj Velji Mange, and Mr. Raj Arvind Bhanushali) along with PAC Mrs. Shraddha Nikunj Mange. The offer is to acquire up to 26,76,180 equity shares representing 26% of total paid-up equity shares at Rs. 55 per share, aggregating to maximum consideration of Rs. 14,71,89,900. The offer is made pursuant to Regulation 3(1) of SEBI (SAST) Regulations, 2011 for substantial acquisition of shares accompanied with change in control. The current promoters hold 23.82% and after full acceptance, the Acquirers along with PAC will hold 49.82% of the target company. The tendering period opens on April 15, 2026 and closes on April 28, 2026.
This open offer triggered under SEBI takeover regulations will result in a change of control at Aspira Pathlab. Public shareholders have an opportunity to tender their shares at Rs. 55 per share during the offer period. The acquirers have committed to maintaining the listing status and not delisting the company.